Eli Lilly is making significant strides in increasing access to its weight loss drug, Zepbound, by offering higher doses in single-dose vials through its direct-to-consumer platform, LillyDirect. The pharmaceutical giant has introduced these vials in 7.5 milligram and 10 milligram doses, priced competitively at $499 per month for the initial prescription and any subsequent refills within 45 days. This move comes as a strategic effort to cater to patients who are financially responsible for their treatments and are enrolled in Medicare or employer-sponsored health plans that do not cover obesity medications.
In addition to the higher doses, Eli Lilly also provides lower-dose options of Zepbound in 2.5 milligram and 5 milligram vials. The 2.5 milligram vial is available at $349, while the 5 milligram vial is priced similarly to the higher doses at $499. These prices are notably lower than the typical monthly list price for Zepbound, making it a more accessible option for those seeking weight loss treatment. Patients can purchase these single-dose vials through LillyDirect's self-pay pharmacy section, with the added convenience of a home-delivery service.
The home-delivery option utilizes a third-party online pharmacy to fulfill prescriptions and deliver them directly to patients, streamlining the process for those with a prescribed treatment from Eli Lilly. This initiative has been met with positive reception, as approximately 10% of new patients entering the obesity market are opting to use Zepbound via LillyDirect’s self-pay pharmacy.
Eli Lilly has noted that the ease of manufacturing single-dose vials compared to autoinjector pens, which cost around $1,000 per month before insurance, has played a crucial role in their strategy. By expanding the U.S. supply of Zepbound amid rising demand, the company aims to alleviate the weight loss drug shortage that previously affected the market. The U.S. Food and Drug Administration (FDA) has since declared this shortage over, which will soon limit many compounding pharmacies from producing cheaper versions of the drug.
"Don't rely on knockoffs that are not approved by the FDA for safety, efficacy and quality."
This statement underscores the importance of using FDA-approved medications like Zepbound, as opposed to unverified alternatives.
While Eli Lilly has not disclosed specific figures regarding patient orders from LillyDirect, the company describes the uptake as "really good." This suggests a growing acceptance and utilization of Eli Lilly's direct-to-consumer model for obtaining Zepbound.